Biochemical disease-free survival rates following definitive low-dose-rate prostate brachytherapy with dose escalation to biologic target volumes identified with SPECT/CT capromab pendetide

Rodney J. Ellis, Hang Zhou, Edward Y. Kim, Pingfu Fu, Deborah A. Kaminsky, Bruce Sodee, Valdir Colussi, Waseet Z. Vance, John P. Spirnak, Carolyn Kim, Martin I. Resnick

Research output: Contribution to journalArticlepeer-review

28 Scopus citations

Abstract

Purpose: To report biochemical disease-free survival (bDFS) after conformal brachytherapy with dose escalation to biological target volumes (BTVs) identified by Capromab Pendetide with single photon emission computed tomography and computed tomography image fusion (SPECT/CT). Methods and materials: Two hundred thirty-nine (T1c-T3b NxM0) consecutive patients were evaluated by SPECT/CT before treatment. Intraprostatic SPECT/CT BTVs were identified and targeted for 150% dose escalation during brachytherapy seed implant (SI). Patients received either SI alone (n = 150) or external beam radiation therapy (EBRT) plus SI boost (EBRT + SI) (n = 89), with (n = 50) and without (n = 189) neoadjuvant hormone ablation therapy. Risk factors (RF) (prostate-specific antigen [PSA] >10 ng/mL, Stage ≥T2b, and Gleason grade ≥7) defined risk group (RG) categories [none, 1, and ≥2 RF define low, intermediate, and high RG] for bDFS calculations using four failure criteria: American Society for Therapeutic Radiology and Oncology (ASTRO) consensus definition, PSA >1.0 ng/mL (PSA >1), PSA >0.5 ng/mL after nadir (PSA >0.5), and PSA nadir + 2 ng/mL rise in PSA clinical nadir (CN + 2). Median followup was 47.2 months (range, 24.8-96.1). Results: Seven-year actuarial bDFS rates were 88.0%, 82.1%, 80.4%, and 79.9% using the ASTRO, PSA >1, PSA >0.5, and CN + 2 failure criteria, respectively. ASTRO-defined bDFS rates were 96.0%, 87.0%, and 72.5% for low, intermediate, and high RG's. Conclusion: The data presented here demonstrate the feasibility of performing SPECT/CT BTV dose escalation in a mature series.

Original languageEnglish (US)
Pages (from-to)16-25
Number of pages10
JournalBrachytherapy
Volume6
Issue number1
DOIs
StatePublished - Jan 2007

All Science Journal Classification (ASJC) codes

  • Oncology
  • Radiology Nuclear Medicine and imaging

Fingerprint Dive into the research topics of 'Biochemical disease-free survival rates following definitive low-dose-rate prostate brachytherapy with dose escalation to biologic target volumes identified with SPECT/CT capromab pendetide'. Together they form a unique fingerprint.

Cite this